azacitidine,venetoclax,pivekimab sunirine
abbvie,roche,immunogen
['omg', 'nct04086264', 'aza+', 'pivekimab', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'aza ', '+aza', 'leusm']
congress | #ash22
naval daver , presented phase ib/ii trial of pivekimab sunirine (pvek)+aza+ven triplet in r/r aml. in 91 patients, orr = 45% and composite cr = 25% (duration 7.7 months), with a manageable safety profile. #leusm 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm